Vaccines in Pregnancy: An Update on Recommendations From CDC's Advisory Committee on Immunization Practices

Birth Defects Research, Journal Year: 2025, Volume and Issue: 117(2)

Published: Feb. 1, 2025

Vaccinations in pregnancy are an essential part of prenatal care and play a critical role protecting both pregnant persons their infants from certain infectious diseases. In the United States, recommendations for vaccines made through comprehensive review currently available scientific literature, including clinical trials post-marketing surveillance data, by Advisory Committee on Immunization Practices (ACIP). The ACIP is advisory committee to US Centers Disease Control Prevention (CDC), comprised medical public health experts who develop evidence-based guidelines vaccinations, persons. has several work groups that evidence ongoing basis, full-committee meetings held at least three times year. As more data regarding safety efficacy become available, these continue evolve. To recommendations, carefully considers risks exposure agents against potential vaccination. We here current vaccinations use Recommendations divided into four categories: recommended during pregnancy, under circumstances, not or contraindicated without specific recommendations. ensure optimal healthcare providers need be familiar with

Language: Английский

---

A Post-Authorisation Safety Study of a Respiratory Syncytial Virus Vaccine in Pregnant Women and Their Offspring in a Real-World Setting: Generic Protocol for a Target Trial Emulation

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 272 - 272

Published: March 5, 2025

Background: Assessing the real-world safety of preventive products against respiratory syncytial virus (RSV) in pregnant women holds significant public health implications, especially as vaccination programs become more widespread. This generic protocol describes a post-authorisation study (PASS) to evaluate RSV using target trial emulation framework. Methods: protocol, adapted from an ongoing PASS, is designed framework vaccine women. Emulating conditions have ability minimise confounding and bias. In this pragmatic observational study, RSV-vaccinated are matched (1:N) with unexposed based on gestational age, calendar time, maternal immunocompromised status, high-risk pregnancy. Key adverse outcomes include preterm birth, stillbirth, hypertensive disorders pregnancy, Guillain-Barré Syndrome (GBS), low birth weight (LBW), small for age (SGA). Future studies may add additional per risk profile Global Alignment Immunization Assessment (GAIA) recommendations. Distinguishing measured during pregnancy those assessed at or after crucial analysis interpretation. Conclusions: offers structured approach evaluating vaccines It aims guide researchers designing should be specific settings data availability.

Language: Английский

---

Prevention of respiratory syncytial virus disease across the lifespan in Italy

Pneumonia, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 5, 2025

Abstract Respiratory syncytial virus (RSV) causes substantial morbidity and mortality across the lifespan, with highest burden seen in infants older adults. Recently approved immunizing agents, including long-acting neutralizing monoclonal antibodies a maternal vaccine for passive immunization of newborns, three vaccines adults aged 60 years who are vulnerable to RSV disease, have potential prevent severe RSV-associated disease if implemented successfully. The use these agents will be some Italian regions over next few months, although no consistent timelines or decisions adoption at national level expected. A multidisciplinary group experts neonatology, obstetrics gynecology, respiratory medicine, geriatric hygiene, public health reviewed evidence on prevention present here their considerations implementing an strategy Italy. Given associated burden, it is essential move quickly deploy populations, enhance surveillance accurately detect/predict seasonal trends activity measure impact strategies. Continuing research combined widespread more sensitive testing needed identify populations risk factors. Policies support preventive measures healthcare system, access must accompanied by educational initiatives advocacy promote acceptance HCPs target population.

Language: Английский

---

Recent advances in the prevention and treatment of respiratory syncytial virus disease

Journal of General Virology, Journal Year: 2025, Volume and Issue: 106(4)

Published: April 9, 2025

Respiratory syncytial virus (RSV) is associated with considerable healthcare burden; as such, prevention and treatment of RSV have long been considered a priority. Historic failures in vaccine development had slowed the research field. However, discovery conformational change fusion protein (F) has led to advancements The pharmaceutical landscape drastically changed recent years successful trials both vaccines second-generation mAbs leading licensing roll-out these agents several countries. preventative therapeutic measures will likely significant impact on RSV-related morbidity mortality. there are still gaps protection that immunizations offer should be addressed. Many unanswered questions about infection dynamics subsequent disease focus ongoing research. This review discusses currently licensed pharmaceuticals others recently progressed clinical trials.

Language: Английский

---

Prophylaxis of RSV Infection in Infants

Current Clinical Microbiology Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: April 10, 2025

Language: Английский

---